Navigation Links
Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
Date:12/7/2007

w drug application for CPP-109, its ability to complete such trials on a timely basis within the budgets established for such trials, whether the Company's trials, which are being conducted in the U.S. under FDA good clinical practice guidelines, will evidence that CPP-109 is safe and effective for the treatment of cocaine addiction and methamphetamine addiction, the Company's ability to protect its intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2006 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 that the Company has previously filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
11. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
(Date:10/1/2014)... Dar, Ethiopia, at the occasion of the Leishmaniasis ... 150 African and international leishmaniasis experts, results of ... efficacy monitoring plan, carried out by MSF, ... and Ethiopia, were presented to key decision makers ... of kala-azar with the combination of Sodium Stibogluconate ...
(Date:10/1/2014)... WOODLAND HILLS, CA (PRWEB) October 01, 2014 ... Mamaly Reshad will speak to a group of dental ... week in the northern Spain city of Oviedo. Dr. ... known prosthodontist and lecturer with clients on two continents, ... mouth complex and aesthetic full mouth reconstruction. , “These ...
(Date:10/1/2014)... 2014 Two bicyclists began a journey ... the country in an effort to raise funds and ... The cyclists, a father-daughter team, plan to bike more ... Washington and finishing in Key West Florida. Funds ... Warriors®, a national nonprofit organization that assists post-9/11 service ...
(Date:10/1/2014)... UP4 Probiotics will be donating a portion of ... Network to End Domestic Violence ( http://www.nnedv.org ) during ... nationwide polling that took place during August and September ... “We are proud to have been chosen by your ... UP4 Women’s Probiotics during the month of October,” said ...
Breaking Medicine News(10 mins):Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2
... bones, teeth, and other parts of the body for early ... like something out of science fiction. But those devices are ... current issue of Chemical & Engineering News (C&EN), ACS, weekly ... that these new diagnostic tools will have the ability to ...
... In an international study of patients with a devastating ... have found intriguing evidence that career choice may influence where ... The study was led by Baycrest,s Rotman Research Institute in ... of California, San Francisco and several U.S. and European clinical ...
... (HealthDay News) -- Young people with the kind of irregular ... surgery to fix the problem instead of taking medication first, ... person,s pulse rate to change from minute to minute, can ... condition is rare in younger people and can occur for ...
... researchers have confirmed there is a genetic risk factor ... still needed, these findings will make it possible to ... Barcelona (UB) have discovered that the genetic variant 677C>T ... known in genetic studies) is linked to osteoporotic vertebral ...
... Reporter , TUESDAY, Sept. 21 (HealthDay News) -- Living ... The rigors of having to lose weight, strictly limit ... medications lead many people to disregard their doctor,s orders. ... counseling and reading materials on how to manage heart ...
... clinical trials and 11 systematic reviews of trials published every ... we ever cope?, ask Hilda Bastian, Paul Glasziou, and Sir ... also decry the continued poor quality of many of these ... evidence, the authors recommend that we must now reduce unnecessary ...
Cached Medicine News:Health News:For sufferers of an early-onset dementia, career choice may determine location of disease in brain 2Health News:For sufferers of an early-onset dementia, career choice may determine location of disease in brain 3Health News:Surgery May Be Best for Irregular Heartbeat in Young 2Health News:Genetic factor in osteoporosis discovered 2Health News:Counseling May Not Help Heart Failure Patients Comply With Rx 2Health News:Counseling May Not Help Heart Failure Patients Comply With Rx 3
(Date:10/1/2014)... 1, 2014   Cypher Genomics, Inc., the ... J. Patrick Ravenel as chief technology officer. Ravenel ... systems experience and a proven track record of designing ... "Patrick has been recognized as a top designer ... is known industry-wide for delivering innovative products that operate ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 This report ... Million by the following Product Categories: Enteral Feeding Pumps, Nasogastric ... analytics for the US Canada, Japan , ... Latin America , and Rest of World. ... through 2018. Also, a six-year historic analysis is provided for ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
... Microfluidic Systems, a privately-held company, announced today ... area of automated biological sample processing and detection. ... Automatically Lyse A Sample".  This patent covers a ... controls critical conditions such as temperature, power, and ...
... FOUNTAIN HILLS, Ariz., Sept. 23 Sunridge International ... today that it has shipped its first order ... for several Middle Eastern countries.  AME plans to ... throughout the region, while simultaneously conducting a short ...
Cached Medicine Technology:Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection. 2Sunridge Ships First Order to the Middle East 2
Inquire...
Inquire...
Inquire...
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
Medicine Products: